An International Journal of Otorhinolaryngology Clinics

Register      Login

VOLUME 10 , ISSUE 2 ( May-August, 2018 ) > List of Articles

ORIGINAL ARTICLE

Clinical Profile of Otomycosis in a Sub-saharan African Tertiary Health Center

Sanyaolu A Ameye, Adekunle Adeyemo, Josephine A Eziyi, Yemisi B Amusa

Keywords : Cohort study, Ear, Fungal, Otalgia, Otoscopy, Ototopic medication, Pruritus

Citation Information : Ameye SA, Adeyemo A, Eziyi JA, Amusa YB. Clinical Profile of Otomycosis in a Sub-saharan African Tertiary Health Center. Int J Otorhinolaryngol Clin 2018; 10 (2):52-55.

DOI: 10.5005/jp-journals-10003-1290

License: CC BY-NC 3.0

Published Online: 00-08-2018

Copyright Statement:  Copyright © 2018; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Aims: This study is aimed at determining the presentation, predispositions, types and treatment outcomes of patients diagnosed with otomycosis in our center. Materials and methods: We reviewed 83 cases of otomycosis who visited the otorhinolaryngology clinic of our center in the period of 5 years. Diagnosis of otomycosis was clinically based on presentation and findings on otoscopic appearance. Results: Records of 83 cases of otomycosis consisting of 40 males and 43 females were analysed. The mean age was 43.19 ± 20.74 years. Twenty-eight (33.7%) patients were asymptomatic with the otomycosis discovered following otoscopy during a clinic visit. Pruritus, ear ache and hearing loss were the commonest complaints among the symptomatic patients. Unilateral disease was seen in 57 (68.7%) of the patients and bilateral disease in 23 (27.7%) of the patients. The affected side was not stated in 3 (3.6%) of the patients. Examination findings revealed in most cases (78, 94.0%) reveal presence of fungal debris. The use of ototoptic medication was noted as the risk factor for more three-quarter of those with identifiable risk factor. Total fifty-one (61.4%) patients had complete resolution. Conclusion: We found otomycosis to be predominantly an adult disease and it is an incidental finding many case. The overall outcome is good regardless of the mode of treatment employed. Clinical significance: The limitation to due to non-available of a particular mode of treatment should not impair obtaining a good outcome when managing otomycosis.


PDF Share
  1. Mugliston T, O'donoghue G. Otomycosis—a continuing problem. The Journal of Laryngology & Otology 1985 Apr;99 (04):327-333
  2. Pontes ZB, Silva AD, Lima Ede O, Guerra Mde H, Oliveira NM, Carvalho Mde F, et al. Otomycosis: a retrospective study. Brazilian Journal of otorhinolaryngology 2009 May-Jun;75 (3):367-370
  3. Gharaghani M, Seifi Z, Zarei Mahmoudabadi A. Otomycosis in iran: a review. Mycopathologia 2015 Jun;179(5-6): 415-424
  4. Viswanatha B, Sumatha D, Vijayashree MS. Otomycosis in immunocompetent and immunocompromised patients: comparative study and literature review. Ear, nose, & throat journal 2012 Mar;91(3):114-21
  5. Chen D, Lalwani AK, House JW, Choo D. Aspergillus mastoiditis in acquired immunodeficiency syndrome. Otology & Neurotology 1999 Sep;20(5):561-567
  6. Prasad SC, Kotigadde S, Shekhar M, Thada ND, Prabhu P, D'Souza T, et al. Primary otomycosis in the Indian subcontinent: predisposing factors, microbiology, and classification. International journal of microbiology 2014 Apr;2014:1-9
  7. Hsu C-L, Chen C-W, Wang H-K. Iatrogenic invasive otomycosis. Tzu Chi Medical Journal 2011 Jun;23(2):66-68
  8. Slack CL, Watson DW, Abzug MJ, Shaw C, Chan KH. Fungal mastoiditis in immunocompromised children. Archives of Otolaryngology–Head & Neck Surgery 1999 Jan;125(1):73-75
  9. Jackman A, Ward R, April M, Bent J. Topical antibiotic induced otomycosis. International journal of pediatric otorhinolaryngology 2005 Jun;69(6):857-860
  10. Munguia R, Daniel SJ. Ototopical antifungals and otomycosis: a review. International journal of pediatric otorhinolaryngology 2008 Apr;72(4):453-459
  11. Lageju N, Shahi S, Goil N. Clinical profile of Otomycosis: a hospital based study at central terrain region of Nepal. Janaki Medical College Journal of Medical Science 2016;3(1):20-24
  12. Ho T, Vrabec JT, Yoo D, Coker NJ. Otomycosis: clinical features and treatment implications. Otolaryngology--Head and Neck Surgery 2006 Nov;135(5):787-791
  13. Mgbe R, Umana A, Adekanye A, Offiong M. Otomycosis-A Management Challenge In Calabar, South-South Nigeria. The Internet Journal of Third World Medicine 2011;9(2):1-5
  14. Fasunla J, Ibekwe T, Onakoya P. Otomycosis in western Nigeria. Mycoses 2008 Jan;51(1):67-70
  15. Paulose K, Al Khalifa S, Shenoy P, Sharma R. Mycotic infection of the ear (otomycosis): a prospective study. The Journal of Laryngology & Otology 1989 Jan;103(01):30-35
  16. Ozcan KM, Ozcan M, Karaarslan A, Karaarslan F. Otomycosis in Turkey: predisposing factors, aetiology and therapy. The Journal of Laryngology & Otology 2003 Jan;117(1):39-42
  17. Kumar A. Fungal spectrum in otomycosis patients. JK Science 2005 Jul-Sep;7(3):152-155
  18. Arndal E, Glad H, Homoe P. Large discrepancies in otomycosis treatment in private ear, nose, and throat clinics in Denmark. Danish medical journal 2016 May;63 (5)
  19. Kurien M, Mathew J, Job A, Zachariah N. Ludwig's angina. Clin Otolaryngol 1997 Jun;22(3):263-265.
  20. Hamza NS, Farrel J, Strauss M, Bonomo RA. Deep fascial space infection of the neck: A continuing challenge. South Med J 2003 Sep;96(9):928-932.
  21. Bansal A, Miskoff J, Lis RJ. Otolaryngologic critical care. Crit Care Clin 2003 Jan;19(1):55-72.
  22. Folz BJ, Tennie J, Lippert BM, Werner JA. Natural history and control of epistaxis in a group of German patients with Rendu–Osler–Weber disease. Rhinology 2005 Mar;43(1):40-46.
  23. Wirsching KE, Kuhnel TS. Update on clinical strategies in hereditary hemorrhagic telangiectasia from an ENT point of view. Clin Exp Otorhinolaryngol 2017 Jun;10(2):153-157.
  24. Rotenberg B, Noyek S, Chin CJ. Radiofrequency ablation for treatment of hereditary hemorrhagic telangiectasia lesions: “how i do it”. Am J Rhinol Allergy 2015 May-Jun;29(3): 226-227.
  25. Joshi H, Woodworth BA, Carney AS. Coblation for epistaxis management in patients with hereditary haemorrhagic telangiectasia: a multicenter case series. J Laryngol Otol 2011 Nov;125(11):1176-1180.
  26. Mortuaire G, Boute O, Hatron PY, Chevalier D. Pilot study of submucosal radiofrequency for epistaxis in hereditary hemorrhagic telangiectasia. Rhinology 2013 Dec;51(4):355-360.
  27. Kumar PS, Matthews CR, Joshi V, de Jager M, Aspiras M. Tobacco smoking affects bacterial acquisition and colonization in oral biofilms. Infect Immun 2011 Nov;79(11): 4730-4738.
  28. Namiot Z, Namiot DB, Kemona A, Gołebiewska M, Bucki R. The effect of cigarette smoking and alcohol consumption on efficacy of Helicobacter pylori eradication. Pol Arch Med Wewn 2000 Sep;104(3):569-574.
  29. Linder JA, Sim I. Antibiotic treatment of acute bronchitis in smokers: a systematic review. J Gen Intern Med 2002 Mar;17(3):230-234.
  30. Lee WK, Ramanathan M Jr, Spannhake EW, Lane AP. The cigarette smoke component acrolein inhibits expression of the innate immune components IL-8 and human betadefensin 2 by sinonasal epithelial cells. Am J Rhinol 2007 Nov-Dec;21(6):658-663.
  31. Kamath PM, Shenoy VS, Mittal N, Sharma NK. Microbiological analysis of paranasal sinuses in chronic sinusitis—a south Indian coastal study. Egypt J Ear Nose Throat All Sci 2013 Nov;14(3):185-189.
  32. Bezerra TF, Pádna FG, Ogawa AI, Gebrim EM, Saldiva PH, Voegels RL. Biofilms in chronic rhinosinusitis with nasal polyps: pilot study. Braz J Otorhinolaryngol 2009 Nov- Dec;75(6):788-793.
  33. Hashemi M, Sadeghi MMM, Omrani MR, Torabi MA. Microbiology and antimicrobial resistance in chronic resistant rhino sinusitis with or without polyp after functional endoscopic sinus surgery. J Res Med Sci 2005;10(3):167-171.
  34. Farahani F, Youse Mashouf R, Hashemian F, Esmaeili R. Antimicrobial resistance patterns of aerobic organisms in patients with chronic rhinosinusitis in Hamadan, Iran. Avicenna J Clin Microb Infec 2014 Aug;1(2):e18961..
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.